

Anti-atherosclerotic mechanism of  
protocatechuic aldehyde and its  
relationship with G protein-coupled  
estrogen receptor-1

Byung Soo Kong

Department of Medical Science

The Graduate School, Yonsei University

Anti-atherosclerotic mechanism of  
protocatechuic aldehyde and its  
relationship with G protein-coupled  
estrogen receptor-1


Directed by Professor Eun Jig Lee

The Doctoral Dissertation  
submitted to the Department of Medical Science,  
the Graduate School of Yonsei University  
in partial fulfillment of the requirements for the degree of  
Doctor of Philosophy


Byung Soo Kong

December 2014


This certifies that the Doctoral Dissertation  
of Byung Soo Kong is approved.




Thesis Supervisor: Eun Jig Lee




Thesis Committee Member #1: Mi Ran Seo



Thesis Committee Member #2: Byung Wan Lee



Thesis Committee Member #3: Seok Min Kang



Thesis Committee Member #4: Sahng Wook Park

The Graduate School  
Yonsei University

December 2014

## Acknowledgements

실험실에 들어온 것은 아마 하나님의 인도하심이 없었다면 가능하지 않았을 것 같습니다. 연세대학교 대학원에 들어와서 이은직 교수님을 뵙고 또 실험실을 선택하는 과정 중에 너무나도 좋으신 분들을 많이 예비해 두셨고 학교생활 말고도 타향살이로 쉽지 않았을 뻔했던 많은 사소한 부분에서 채워주심을 느낄 수 있었습니다. 대학원 생활 동안 여러 면으로 도움을 주신 이은직 교수님께 감사합니다. 교수님께서 저에 대한 믿음과 인내로 기다려주시지 않았다면 쉽지 않았을 것 같습니다. 첫 만남 때 영어 인터뷰로 당황했던 기억부터 첫 회식때 우물쭈물 자기 소개를 했던 것 그리고 공개 발표까지 많은 일들이 있었던 4 년이란 시간동안 저를 이끌어주신 교수님과 여러 실험실 구성원분들께 감사의 말씀을 전하고 싶습니다. 4 년 동안 거처를 마련해주신 혜화동 혜성 교회와 후배 양종이 부모님께 감사드립니다. 서울 객지 생활을 하면서 집은 저에게 정말 고마운 안식처가 되었습니다. 실험실 생활에서 정신적 버팀목이 되어준 철룡이형, 양종이, 정우와 Glang 에게 정말 고맙습니다. 실험에 관해 도움을 주신 신경과 권일 형과 미국에 계시는 성결이형 감사합니다. 잔일도 마다하지 않고 친구의 일이면 제일 먼저 나서서 도와주는 오랜 친구 동욱이에게 정말 고맙습니다. 명절 때마다 갈 곳 없는 저에게 따뜻한 사랑으로 가족처럼 품어주신 동희형, 동주형, 경혜누나와 서림 형수님 및 동욱이 가족에게 정말 감사드립니다. 그리고 예배의 자리에서 항상 든든한 후원자가 되어준 삼일교회 지체 (민영누나, 정연이, 한나, 지연이, 자영이)들에게 감사합니다. 마지막으로 저를 항상 기도와 눈물로 사랑해주시는 부모님과 동생에게 감사의 말씀을 전합니다.

2014 년 12 월 16 일 실험실에서

## Table of contents

|   |    |
|---|----|
| ABSTRACT .....  | 1  |
| I. INTRODUCTION .....   | 3  |
| II. MATERIALS AND METHODS .....   | 6  |
| 1. Reagents, Antibodies and Assay kits .....  | 6  |
| 2. Ethics Statement .....   | 6  |
| 3. Cell Culture .....   | 7  |
| 4. Western Blotting .....   | 7  |
| 5. Animal Model – Common Carotid Balloon injury .....   | 8  |
| 6. Measurement of ROS (Reactive Oxygen Species) in HUVECs<br>.....                                | 9  |
| 7. cAMP assay in HUVECs .....   | 9  |
| 8. Ex vivo Sprague Dawley Rat's thoracic aorta culture .....                                      | 10 |
| 9. Sprout Ring assay .....  | 10 |
| 10. Vascular Histology and Immunohistochemical procedures ...                                     | 11 |
| 11. MTS assay .....   | 12 |
| 12. Quantification of in vitro results, sprout length and<br>neointima size of Rat arteries ..... | 12 |
| III. RESULTS .....  | 14 |
| 1. PCA increases GPER-1 expression in HUVECs and<br>Sprague Dawley rat aortas .....               | 15 |
| 2. PCA decreases ROS production in HUVECs .....   | 17 |

|   |    |
|---|----|
| 3. PCA inhibits inflammatory signaling .....  | 19 |
| 4. PCA inhibits angiogenesis .....  | 22 |
| 5. PCA accelerates re-endothelization in balloon-injured arteries<br>.....                    | 24 |
| 6. PCA inhibits neointima formation in balloon-injured<br>common carotid arteries (CCA) ..... | 28 |
| 7. The mode of action of PCA and GPER-1 antagonist .....                                      | 31 |
| IV. DISCUSSION .....  | 33 |
| V. CONCLUSION .....   | 38 |
| REFERENCES .....  | 39 |
| ABSTRACT (IN KOREAN) .....  | 45 |

## LIST OF FIGURES

|  |    |
|--|----|
| Figure 1. PCA increases GPER-1 expression in HUVECs and<br>Sprague Dawley rat aortas .....           | 15 |
| Figure 2. PCA decreases ROS production in HUVECs .....   | 18 |
| Figure 3. PCA inhibits inflammatory signaling .....  | 20 |
| Figure 4. PCA inhibits angiogenesis .....  | 23 |
| Figure 5. Protocatechuic aldehyde accelerates<br>reendothelization in balloon-injured arteries ..... | 26 |
| Figure 6. PCA inhibits neointima formation in<br>balloon-injured common carotid arteries (CCAs) ...  | 29 |
| Figure 7. The mode of action of PCA and GPER-1 antagonist ..   | 32 |

Abstract

**Anti-atherosclerotic mechanism of  
protocatechuic aldehyde and its relationship with  
G protein-coupled estrogen receptor-1**

**Byung Soo Kong**

*Department of Medical Science  
The Graduate School, Yonsei University*

(Directed by Professor Eun Jig Lee)

Protocatechuic aldehyde (PCA), a phenolic aldehyde, has been proposed to have therapeutic potency for treatment of atherosclerosis. Although PCA is known to inhibit the migration and proliferation of vascular smooth muscle cells and intravascular thrombosis, the underlying mechanism remains unclear. In this study, I investigated the protective effect of PCA in endothelial cells and injured vessels in association with G protein-coupled estrogen receptor-1 (GPER-1) *in vivo* and *in vitro*.

PCA treatment increased cAMP production in Human Umbilical vein endothelial cells (HUVECs) and GPER-1 expression was increased in both HUVECs and a rat aortic explant. PCA and G1, a GPER-1 agonist, reduced H<sub>2</sub>O<sub>2</sub> stimulated ROS production in HUVECs, whereas G15, a



GPER-1 antagonist, increased ROS production further. This elevation of ROS production was inhibited by treatment of G15 with PCA or G1. TNF $\alpha$  stimulated the expression of inflammatory markers (VCAM-1, ICAM-1 and CD40), phospho-NF- $\kappa$ B, phospho-p38 and HIF-1 $\alpha$ ; however, treatment with PCA or G1 down-regulated this expression significantly. Accordingly, increased expression of inflammatory markers by treatment with G15 was inhibited by treatment with PCA.

Treatment of rat aorta with PCA or G1 showed accelerated re-endothelization of the endothelium and reduced sprouting and neointima formation. However, aortas from G15-treated rats showed decelerated re-endothelization and increased sprouting and neointima formation. The effects of G15 were restored by treatment with PCA or G1. In addition, in the endothelia of these aortas, PCA and G1 increased CD31 and GPER-1 and decreased VCAM-1 and CD40 expression. In contrast, the opposite effect was observed in G15-treated endothelium. These results suggest that GPER-1 might mediate the protective effect of PCA on the endothelium.

---

Key words: protocatechuic aldehyde, human umbilical vein endothelial cells, endothelial dysfunction, atherosclerosis, g protein-coupled estrogen receptor-1

# **Anti-atherosclerotic mechanism of protocatechuic aldehyde and its relationship with G protein-coupled estrogen receptor-1**

**Byung Soo Kong**

*Department of Medical Science  
The Graduate School, Yonsei University*

(Directed by Professor Eun Jig Lee)

## **I. Introduction**

Endothelial dysfunction is an imbalance between vaso-dilating and vaso-constricting substances produced by the endothelium leading to a proinflammatory state and prothrombic properties. Endothelial dysfunction is an important early event in the pathogenesis of atherosclerosis. Mechanisms that participate in endothelial dysfunction include reduced nitric oxide generation, oxidative excess, and upregulation of adhesion molecules.<sup>1,2</sup> Previous studies on atherosclerosis have provided some information on this topic. For example, increased expression of proteins such as VCAM-1, ICAM-1, E-selectin, CD40, lectin-like oxidized LDL receptor-1 (LOX-1),<sup>3</sup> production of matrix metalloproteinases (MMPs)<sup>4</sup> and reactive oxygen species (ROS), and decreased secretion levels of NO<sup>5</sup> contribute to both initiation and progression of atherosclerosis.

To study about subject on the initiation and progression of atherosclerosis, it is quiet difficult to avoid mentioning about estrogen. It is well known that the estrogen is involved in sexual development and reproduction, but only recently, current researches show that it is also involved in many physiological processes including cardiovascular system. Results from the previous studies suggest that estrogen act to protect women before menopause against coronary heart disease,<sup>6</sup> to decrease the risk of coronary heart disease on women after menopause,<sup>7</sup> and to protect animals from atherosclerosis.<sup>8</sup> From many studies involving the ones that I already have listed show us how estrogen could attenuate cardiovascular diseases by inhibition of immutable or intrinsic factors (age, sex and heredity) and modifiable or extrinsic factors (diet, obesity, tobacco consumption, stress and physical activity). Dyslipidemia, normally taking place at a condition where low-density lipoprotein (LDL) cholesterol becomes higher and high-density lipoprotein (HDL) cholesterol falls, has both influences from immutable and modifiable factors. Interestingly, lipoprotein concentration among premenopausal women differs from men; total and LDL cholesterol are lower while HDL cholesterol is higher.<sup>9</sup> However, post-menopausal women become to have higher LDL cholesterol than HDL in comparison to pre-menopausal women. This makes higher risk of dyslipidemia and atherosclerosis for post-menopausal women. However, there is little known about the relationship between estrogen and endothelial dysfunction and this study will be focused on this subject.

As it was mentioned earlier, estrogen has protective effects against cardiovascular diseases, and its receptors ER  $\alpha$  and ER  $\beta$  have been shown to mediate anti-atherogenic effects. Recently, a third membrane-bound ER

has emerged, G protein-coupled estrogen receptor-1 (GPER-1), that has beneficial effects on the cardiovascular system. GPER-1 is a seven transmembrane-domain G protein-coupled receptor (GPCR) that binds to 17 $\beta$ -estradiol (E2) with high affinity and mediates estrogenic signals.<sup>10</sup> GPER-1 is widely expressed in human tissues, including the cardiovascular system.<sup>11,12</sup> It was recently found that selective activation of GPER-1 potently inhibits the growth of human vascular smooth muscle cells.<sup>13</sup> To find the role of GPER-1 on endothelial protection, G1 (GPER-1 agonist) and G15 (GPER-1 antagonist) have been evaluated. These pharmacological agents are currently used most frequently as tools for investigating the role of GPER-1 in various systems.<sup>10</sup> In this study, both agents were used to modulate GPER-1 *in vitro* and *in vivo* to investigate the protective role protocatechuic aldehyde (PCA) has in endothelial dysfunction through GPER-1.

Protocatechuic aldehyde (PCA) is a phenolic aldehyde found in the aqueous extract of *Salvia Miltiorrhiza* that has recently been reported for its anti-oxidative effects. It was recently reported that PCA reduces myocardial infarct size and the activities of creatine kinase-MB and cardiac troponin in serum.<sup>14</sup> Also, it can inhibit migration and proliferation of vascular smooth muscle cells and intravascular thrombosis.<sup>15</sup> However, the underlying mechanism of PCA on reducing inflammation and its effects on endothelial dysfunction remains to be determined. In this study, we investigated the protective effect of PCA on endothelial cells and injured vessels *in vivo* in association with GPER-1.

## **II. Materials and Method**

### **1. Reagents, Antibodies and Assay kits**

Protocatechuic aldehyde (PCA) and GPER-1 agonist, G1 (Figure 1 A) were purchased from Sigma Aldrich (St. Louise, MO, USA). GPER-1 antagonist, G15 was purchased from Calbiochem (San Diego, CA, USA). TNF- $\alpha$  and rat PDGF-BB were purchased from R&D Systems (Minneapolis, MN, USA).

Antibodies for western blot analysis against GPER-1 (sc-134576), VCAM-1 (sc-8304), ICAM-1 (sc-7891), CD31 (sc-1506), CD40 (sc-975) were purchased from Santa Cruz (Delaware, CA, USA). phospho-MAPK (#9106S), NF $\kappa$ B (#4767), phospho-NF $\kappa$ B (#3033S), and HIF-1 $\alpha$  (#3716S) were purchased from Cell Signaling Technology (Danvers, MA, USA).

CM-H2DCFDA kit (#C6827) was bought from Invitrogen (Carlsbad, CA, USA) for ROS assay. Cultrex<sup>®</sup> BME matrigel (3431-005-01) was bought from Trevigen (Gaithersburg, MD, USA) for sprout ring assay. MTS assay kit (G3580) was purchased from Promega (Madison, WI, USA). Cyclic AMP XP<sup>™</sup> Assay kit (#4339) was brought from Cell signaling (Danvers, MA, USA).

### **2. Ethics Statement**

All animals procedures were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Yonsei University Health System (approval number: 2010-0268) and were

performed in strict accordance with the Association for Assessment and Accreditation of Laboratory Animal Care.

### **3. Cell Culture**

Primary HUVECs were obtained from GIBCO (C-003-5C). HUVECs were cultured in EBM-2 (CC-3129) supplemented with serum kit (CC-4176) purchased from Lonza (Walkersville, MD, USA). Cells were maintained at 37°C humidified atmosphere of 5% CO<sub>2</sub> incubator in collagen-coated dish supplied from Sigma Aldrich (C9791). The medium was changed every 2 days. For the experiments, HUVECs passage 3~8 were used 2 hours after serum depletion.

### **4. Western Blotting**

Western blot analysis was performed using antibodies against GPER-1, VCAM-1, ICAM-1, CD31, CD40, phospho-MAPK, phospho-NFκB, and HIF-1α. Cells were lysed in buffer containing 10 mM Tris, 400 mM NaCl, 1 mM EDTA, and 0.1% (v/v) NP-40. Protein concentration of the cell was determined by the Bradford method.<sup>15</sup> Equal amounts of the whole protein extract were subjected on 10% SDS PAGE followed by semi-dry Western blotting. Subsequently, membranes were blocked with 5% BSA in TBST (50 mM Tris-HCl, pH 7.5 and 150 mM NaCl containing 0.05% (v/v) Tween 20). Blots were probed overnight with the dilutions of antibodies listed above in 5% (w/v) BSA containing TBST. After incubation with a secondary anti-rabbit antibody coupled to horseradish peroxidase,

immunocomplexes were visualized by enhanced chemi-luminescence purchased from Abfrontier (LF-QC0101, Seoul, Korea).

## **5. Animal model – Common Carotid Balloon Injury**

Male Sprague Dawley rats (SD rats, ORIENT-Charles River Technology, Seoul, Korea) weighing 200~225 were housed in a temperature-controlled environment (24~26 °C) with a 12/12-hours reversed light and dark cycle, in a plastic cage with soft bedding, and given with a free access to tap water and standard laboratory chow.

7 weeks old rats were randomly divided into seven groups and they were daily fed by intraperitoneal administration with the following amounts: Group 1 – Sham operated; Group 2 – Balloon injury; Group 3 – PCA (100mg/kg) with balloon injury; Group 4 – G1 (3.0 mg/kg) with balloon injury; Group 5 – G15 (3.0 mg/kg) with balloon injury; Group 6 – G15 (3.0 mg/kg) and PCA (100mg/kg) with balloon injury; Group 7 – G15 (3.0 mg/kg) and G1 (3.0 mg/kg) with balloon injury.

For operative procedures, SD Rats were anesthetized with 5% isoflurane in a mixture of 70 % N<sub>2</sub>O and 30% O<sub>2</sub> and it was maintained with 2% isoflurane. Body temperatures were constantly checked with a rectal probe to maintain at 37.0 ± 0.2 °C using a homeothermic blanket control unit and a heating pad (Harvard Apparatus, Holliston, MA, USA) during this procedures. After 2 weeks of intraperitoneal administration of substances, rats' left common carotid arteries were isolated and a 2F Forgarty catheter (Edwards Lifesciences, Irvine, CA, USA) was introduced through the external carotid arteriotomy incision, advanced to the aortic arch, inflated to

produce moderate resistance, and gradually withdrawn 7 times as previously reported.<sup>16</sup>

For Neointimal Formation experiment, animals were injected with each substance for 4 weeks more after 2 days of recovery and then sacrificed.

For Re-endothelization assay, animals were injected with each substance for 1 week more after 2 days of recovery and then injected with Evans Blue through tail vein. They were left injected for 30 minutes and then sacrificed to obtain the common carotid artery for evaluation. During these procedures, every effort was made to minimize animal usage and their sufferings.

## **6. Measurement of ROS in HUVECs**

Levels of cellular reactive oxygen species were measured using the fluorescent probe 5-(and-6)-chloromethyl-2', 7'-difluorodihydrofluorescein diacetate (CM-H2DFFDA). To prepare for the ROS assay, HUVECs cultured in EBM-2 supplemented with serum kit were changed into serum free media with 0.1% serum. Sample is treated for 24 hours and then, 1 hour of H<sub>2</sub>O<sub>2</sub> 100uM is added to each dish. After that, ROS assay procedures were followed as it was described from other studies.<sup>17</sup> Samples were analyzed with FACS Calibur (BD Biosciences, Franklin Lakes, NJ, USA).

## **7. cAMP assay in HUVECs**

cAMP assay kit was purchased from Cell Signaling (Cell Signaling, Danvers, MA, USA). HUVECs were seeded on 96 well plates in EBM-2



media with serum kit. After a day of incubation, serum media were replaced with serum free EBM-2 media with 0.1% FBS serum. After 2 hours of incubation, appropriate substances (Control, PDGF, PCA, G1, G15, G15+PCA, G15+G1) were added and incubated for 1 hr. Then steps were followed as it is stated on the manufacturer's manual from Cell Signaling.

## **8. Ex vivo Sprague Dawley Rat's thoracic aorta culture**

Male Sprague Dawley Rats (100g) were housed in a controlled environment as previously described. After one week of stabilization, under anesthesia, rats were sacrificed and thoracic aortas were obtained. Thoracic aortas were chopped into several pieces and placed on Cell Culture Insert (PICM03050) purchased from Millicell® (Billerica, MA, USA) in 6-well plate.

Aortas were maintained in EBM-2 media with serum kit for one day to make them adapt to the experiment condition. Before the treatment of PCA, EBM-2 media with serum kit were removed and replaced with EBM-2 serum free media. After 2 hours of serum depletion, PCA were added in time dependent manner. After the treatment, aortas were stored in 4% paraformaldehyde for fixation in 4 °C condition.

## **9. Sprout Ring assay**

This method was used with some modifications by following previous work originally reported for mice aorta.<sup>18</sup> Under anesthesia, thoracic aortas were removed from rat of 100 grams and transferred to a 50

ml conical tube containing ice-cold serum-free EBM-2 medium. The peri-aortic fibro-adipose tissue was carefully removed with fine micro-dissecting forceps not to damage the aortic wall. Half a millimeter long aortic rings (approximately 25 per aorta) were sectioned. Ring-shaped explants of rat aorta were then embedded in BME Matrigel on Coverglass Bottom dish. EBM-2 serum media was added into the dish and left to be incubated for 3 days. 3 days later, PCA, G1, G15, G15 and PCA, and G15 and G1 were added. The cultures were kept at 37°C in a humidified environment for a week and examined every day with an Olympus microscope at appropriate magnification.

## **10. Vascular Histology and Immunohistochemical procedures**

Rat arteries were perfused with saline, removed, and fixed in 4% paraformaldehyde for 24 hours in 4°C. Then, they were embedded in paraffin and prepared in 4 µm cross sections. Rat aortas were stained with hematoxylin and eosin using standard protocol.<sup>19,20</sup> For immunohistochemical analyses, sections were deparaffinized in xylene, rehydrated in graded ethanol solutions and washed with distilled water as described from other studies.<sup>21</sup> Sections were blocked with 5% goat serum (005-000-121, Jackson ImmunoResearch, West Grove, PA, USA) in antibody diluent (S2022, Dako, Glostrup, Denmark) for 30 minutes and incubated overnight at 4°C with following antibodies: GPER-1, CD40, CD31 and VCAM-1 (1:150). After washing three times in TBS-T, slides were incubated for 1 hr with a biotinylated secondary antibody (Vector Laboratories, Burlingame, CA, USA). After rinsing three times in TBS-T,

RTU horseradish peroxidase streptavidin (SA5704, Vector Laboratories) was applied and the slides are incubated for 10 minutes. For color development, 3,3'-diaminobenzidine (DAB, D5637, Sigma) was used.

## **11. MTS assay**

VSMCs grown on 100mm are trypsinized and seeded on 96 well plates. After 24 hours of incubation in DMEM serum media, serum media are replaced with serum free DMEM media. After 24 hours of serum depletion, appropriate drugs (Control, PDGF, PCA, G1, G15, G15 and PCA, G15 and G1) are added in serum free DMEM media to each group. For Control and PDGF group (10 ng/ml), no substances are added. After 24 hours of drug treatment, media are removed and replaced with PDGF added drug-containing DMEM media except for Control group. After 24 hours later, steps are followed as it is stated on the manufacturer's manual from Promega.

## **12. Quantification of in vitro results, sprout length and neointima size of Rat arteries**

To perform image analysis, all images were taken under the same observation condition (light, contrast, magnification). Image analysis was performed by using Scion Image software and results were expressed as mean $\pm$ SEM. Differences between groups for both *in vivo* and *in vitro* results were evaluated using SPSS 18.0 software. Also graphs for Balloon injury,


reendothelization assay and sprout ring assay were done by MedCalc software program.

For morphologic analysis of neointimal formation, six round cross-sections (4  $\mu\text{m}$  thickness) were cut from the approximate middle of the artery. The intimal and medial cross-sectional areas of the carotid arteries were measured, and intima/media ratios were calculated. Antibody against GPER-1 was used for immunohistochemistry.

### **III. Results**

#### **1. PCA increases GPER-1 expression in HUVECs and Sprague Dawley rat aortas**

To assess whether the effect of PCA on human umbilical vein endothelial cells (HUVECs) is mediated through GPER-1, cAMP levels and GPER-1 expression were measured after PCA treatment. PCA increased cAMP levels in a concentration-dependent manner. Significant elevation of cAMP levels was observed at 100  $\mu$ M of PCA. Comparison of elevated cAMP levels between G1 (3.0  $\mu$ M) and PCA stimulation showed that PCA was less potent than G1. GPER-1 expression was increased by PCA treatment in a concentration dependent manner with the highest expression after 6 hrs of incubation compared to that of the control (1.61 fold,  $P < 0.05$ ) (Figure 1C, D). In the *ex vivo* culture of rat aortic explants, 100  $\mu$ M of PCA increased GPER-1 expression after 6 hrs of treatment. (Figure 1E). Also the treatment of PCA in siGPER-1 had increased the expression level of GPER-1 in RT-PCR (Figure 1F).




**Figure 1.** PCA induces expression of GPER-1. **(A)** The chemical structure of PCA and G1. **(B)** HUVECs were treated with G1 (3.0  $\mu$ M) and PCA (10, 50, or 100  $\mu$ M) for 1 hr to measure the levels of cAMP activity. **(C)** HUVECs were treated with PCA (10, 50, or 100  $\mu$ M) for 6 hrs. **(D)** HUVECs were treated with PCA (100  $\mu$ M) over 1, 3, 6, 24 hrs. Blots are representative of 3 independent experiments. Densitometric analyses are presented as the relative ratio of GPER-1 to  $\beta$ -actin. Data are presented as mean $\pm$ SEM; \*  $P < 0.05$ . **(E)** Aortic segments were harvested from Sprague Dawley rats and cultured *ex vivo* in serum-free media with PCA (100  $\mu$ M) over 1, 3, 6, 24 hrs. Segments were then fixed for immunohistochemistry of GPER-1 using 4% paraformaldehyde.

## 2. PCA decreases ROS production in HUVECs

PCA reduced H<sub>2</sub>O<sub>2</sub> stimulated ROS production in HUVECs in a concentration-dependent manner. Treatment with 50 or 100  $\mu$ M of PCA significantly decreased ROS production ( $77.31 \pm 2.56\%$ ,  $P < 0.05$  and  $57.18 \pm 8.33\%$ ,  $P < 0.01$ ) stimulated by 100  $\mu$ M H<sub>2</sub>O<sub>2</sub> for 1 hr (Figure 2A). Comparison between G1 (3.0  $\mu$ M) and PCA (100  $\mu$ M) showed similar decreases in ROS production. Whereas, the GPER-1 antagonist G15 (3.0  $\mu$ M) increased ROS production further to  $132.47 \pm 5.49\%$  ( $P < 0.05$ ). This elevation in ROS production was decreased to  $78.33 \pm 7.73\%$  ( $P < 0.05$ ) and  $100.25 \pm 2.41\%$  ( $P < 0.05$ ) by treatment with PCA or G1, respectively (Figure 2B).






**Figure 2.** Protocatechuic aldehyde decreases ROS production. **(A)** HUVECs were pretreated for 24 hrs with various concentrations (10, 50, 100  $\mu$ M) of PCA. **(B)** HUVECs were pretreated for 24 hrs with PCA (100  $\mu$ M) and G1 (3.0  $\mu$ M) and for 6 hrs with G15 (3.0  $\mu$ M). Then, **(A, B)** HUVECs were treated with H<sub>2</sub>O<sub>2</sub> (100  $\mu$ M/ml) for 1 hr followed by measurement of ROS levels. **(A, B)** Both experiments are representative of 3 independent experiments. Data are presented as mean $\pm$ SEM; \*  $P < 0.05$ , \*\*  $P < 0.005$ , # indicates  $P < 0.05$  compared to the control group.

### 3. PCA inhibits inflammatory signaling

To evaluate whether PCA could down-regulate the inflammation in HUVECs caused by TNF $\alpha$  treatment, HUVECs were pre-treated with PCA (100  $\mu$ M) or G1 (3.0  $\mu$ M) for 24 hours.<sup>15</sup> Then, 10 ng/ml TNF $\alpha$  was added for 6 hours to provoke inflammation. As shown in Figure 3A, TNF $\alpha$  stimulated the expression of VCAM-1, ICAM-1 and CD40; however, PCA down-regulated these expression levels significantly. G1 also down-regulated their expression in a similar manner (Figure 3A).

To investigate inhibition of the NF- $\kappa$ B signaling pathway by treatment with PCA or G1, endothelial cells were pre-treated with PCA (100  $\mu$ M) or G1 (3.0  $\mu$ M) in the presence or absence of TNF $\alpha$  (10 ng/ml, 1 hr). As shown in Figure 3B, TNF $\alpha$  increased the expression of phospho-NF- $\kappa$ B, phospho-p38 and HIF-1 $\alpha$ . This elevated expression was down-regulated significantly by PCA and G1 (Figure 3B).


We also investigated whether G15, an antagonist of GPER-1, affects the expression of inflammatory markers in HUVECs and if PCA could act as a GPER-1 activator to block the activity of G15. As shown in Figure 3C, G15 showed GPER-1 inhibition activity by decreasing the expression level of GPER-1. Also, G15 increased VCAM-1, ICAM-1 and CD40 compared to the control. However, PCA treatment increased GPER-1 and inhibited inflammation markers dramatically.



**Figure 3.** Human umbilical vein endothelial cells (HUVECs) treated with tumor necrosis factor alpha (TNF $\alpha$ ) and G15 induces inflammation. **(A, B)** HUVECs were pretreated with PCA (100  $\mu$ M) and G1 (3.0  $\mu$ M) for 24 hrs. **(A)** treatment with TNF $\alpha$  (10 ng/ml) for 6 hrs. **(B)** treatment with TNF $\alpha$  (10 ng/ml) for 1 hr. **(C)** HUVECs were pre-treated with PCA (100  $\mu$ M) for 24 hrs and then treated with G15 (3.0  $\mu$ M) for 6 hrs. Blots are representative of 3 independent experiments. **(A, B, C)** Densitometric analyses are presented as the relative ratio of ICAM-1, VCAM-1, CD40, HIF-1 $\alpha$ , GPER-1 or phospho-p38 to  $\beta$ -actin. **(B)** Densitometric analyses for phospho-NF- $\kappa$ B are presented as the relative ratio to NF- $\kappa$ B. Data are presented as mean $\pm$ SEM; \* P < 0.05, \*\* P < 0.005, \*\*\* P < 0.001.

#### **4. PCA inhibits angiogenesis**

To investigate the effect of PCA on angiogenesis, the Sprout Ring assay was performed. As shown in Figure 4A, treatment with PCA ( $3.74 \pm 1.89\%$ ,  $P < 0.001$ ) or G1 ( $5.49 \pm 2.83\%$ ,  $P < 0.001$ ) significantly prevented the length of sprouting compared to the serum only group (100.0%). Whereas, the addition of G15 ( $223.9165 \pm 32.96\%$ ,  $P < 0.01$ ) dramatically increased the sprouting of VSMCs. Treatment with PCA or G1 inhibited sprouting dramatically.



**Figure 4.** PCA inhibits angiogenesis. (A) Rat aortas were obtained from Sprague Dawley rats weighing 100 grams. Rat aorta segments placed on Matrigel were stimulated with FBS (10%) for 3 days. Then, the segments were treated with each substance for 48 hrs in media supplemented with FBS (10%). Sprout lengths were measured by using Scion Image software. (A, B) Values represent the means  $\pm$  SEMs of 3 experiments. \*\*\* indicates  $P < 0.001$  compared to the control group. ## and ### indicate  $P < 0.005$  and  $P < 0.001$ , respectively, compared to the PDGF group. §§§ indicates  $P < 0.001$  compared to the G15 group.

## 5. Protocatechuic aldehyde accelerates re-endothelization in balloon-injured arteries

To investigate whether PCA also protects the endothelium through GPER-1 under *in vivo* conditions, endothelial recovery was evaluated after balloon denudation of the carotid artery in rats.<sup>22</sup>


Sprague Dawley rats were pre-treated with the substances for 2 weeks by intraperitoneal injection and then balloon injury of the common carotid artery was performed. Rats were injected with the substances for another 3 days after the surgical procedure. Before the isolation of carotid arteries, rats were injected with Evans Blue through the tail vein and left for 30 min. As shown in Figure 5A, treatment with PCA or G1 accelerated re-endothelization in balloon-injured arterial segments. The re-endothelized area in the PCA- and G1-treated rats was  $69.35 \pm 3.81\%$  ( $P < 0.001$ ) and  $40.21 \pm 5.21\%$  ( $P < 0.01$ ), respectively, compared to the vehicle rats. The effect of PCA on re-endothelization was higher compared to that of G1. G15-treated rats did not show re-endothelization, similar to the vehicle treatment. Treatment of PCA on G15 treated aortas showed effective re-endothelization ( $42.77 \pm 13.17\%$ ,  $P < 0.05$ ), whereas treatment of G1 on G15 treated aortas showed partial effects ( $6.90 \pm 1.52\%$ ,  $P < 0.05$ ) (Figure 5A).

As shown in Figure 5B, immunostaining for CD31, an endothelial marker, showed that the PCA- and G1-treated groups had a clear line of CD31 along the endothelium of the artery. Whereas, the vehicle- or G15-treated groups showed no staining of CD31. This suggests that re-endothelization occurred in PCA- or G1-treated arteries. GPER-1 expression was increased in PCA- and G1-treated endothelium compared to vehicle-


treated arteries. Treatment with G15 decreased expression of GPER-1. Treatment with G15 and PCA or G1 did not suppress GPER-1 completely, but decreased expression of VCAM-1 and CD40 was observed. The expression of VCAM-1 and CD40 was increased by G15 treatment; however, treatment with PCA or G1 decreased their expression (Figure 5B) in the endothelium.



A



B





**Figure 5.** Protocatechuic aldehyde exhibits endothelial protection. **(A)** Re-endothelization of a Sprague Dawley rat carotid artery determined by Evans Blue staining (de-endothelized areas are stained with blue). Ratios of surface covered by endothelium to the total area in sham, vehicle, and injured (Inj) groups treated with different substances as follows: PCA, G1, G15, G15 + PCA, G15 + G1 (n=4 each). **(B)** Cross sections of rat common carotid arteries stained with CD31 antibody 3 days after injury. Also, targets related to inflammatory markers were observed including VCAM-1, CD40 and GPER-1. Data are presented as mean $\pm$ SEM; \*\*\* indicates  $P < 0.001$  compared to the sham group. ## and ### indicate  $P < 0.005$  and  $P < 0.001$ , respectively, compared to the vehicle group. § indicates  $P < 0.05$  compared to the G15 + Inj. group.

## **6. PCA inhibits neointima formation in balloon-injured common carotid arteries (CCAs)**

We investigated the protective effect of PCA and G1 in a balloon injury model. Sprague Dawley rats (n=7) were treated for 2 weeks with the substances before the surgical procedure.<sup>23</sup> After balloon injury of the CCA, rats were treated again with the substances for 4 weeks. After sacrifice, injured CCAs were isolated and paraffin embedded for H&E staining and immunohistochemistry for GPER-1.

Figure 6A shows the representative images of each group treated with drugs along with bar graphs below. The results clearly show the effectiveness of PCA and G1 against neointima formation, whereas G15 increased formation. PCA and G1 attenuated neointimal hyperplasia from  $14.00 \pm 0.95$  inches<sup>2</sup> to  $9.65 \pm 0.76$  inches<sup>2</sup> ( $P < 0.001$ ) and  $8.418 \pm 0.73$  inches<sup>2</sup> ( $P < 0.001$ ), respectively. However, in G15-treated rats, neointima formation dramatically accelerated to  $17.16 \pm 1.06$  inches<sup>2</sup> ( $P < 0.001$ ). The effect of G15 was inhibited by treatment with PCA ( $6.06 \pm 0.39$  inches<sup>2</sup>,  $P < 0.001$ ) or G1 ( $8.45 \pm 0.58$  inches<sup>2</sup>,  $P < 0.001$ ).


Immunohistochemistry revealed that GPER-1 expression was increased in endothelia from rats treated with PCA or G1 compared to that of the vehicle-treated group. Arteries treated with G15 showed very low levels of GPER-1 expression. However, treatment with PCA or G1 restored GPER-1 expression in the endothelium (Figure 6B).



**Figure 6.** The effects of PCA, G1, G15, G15+PCA, and G15+G1 in CCA balloon-injured Sprague Dawley rats. **(A, B)** Seven-week-old Sprague Dawley rats (200 g) were treated with each substance by intraperitoneal injection for 2 weeks and then common carotid arteries from the rats were balloon injured. Substances were injected for another 4 weeks and then sacrificed for **(A)** H & E staining of common carotid arteries. Graph shows the percentage of neointima areas of Sprague Dawley rats from each group (n=7). Measurements were made using Scion Image software. **(B)** immunohistochemistry of rat aortas shows GPER-1 expression in the linings of the aorta from the same tissues used for Figure 5A. Data are presented as mean±SEM; \*\*\* indicates  $P < 0.001$  compared to the sham group. ### indicates  $P < 0.001$  compared to the vehicle group. §§§ indicates  $P < 0.001$  compared to the G15 + Inj. group.

## **7. The mode of action of PCA and GPER-1 antagonist**

To further verify the relationship between PCA and GPER-1 and G15's intervention in this relationship, we have treated G15 to HUVECs to see whether G15 can inhibit the cAMP activity of GPER-1. In Figure 7A shows that G15 has a mild inhibitory effect on cAMP activity. Also, the treatment of G15 with PCA or G1 has decreased activity level mildly compared to PCA or G1 only treated group. This shows that G15, which is unknown for its capability on GPER-1 mechanism, does a slight inhibition on cAMP activity of GPER-1 in HUVECs. Also similar patterns were observed in Supplementary Figure 7B as it mildly inhibits p-AMPK, which is a well-known downstream protein of cAMP, increased by PCA and G1. These data suggest G15's inhibitory effect depend less on cAMP inhibition to cause inflammatory and oxidative effects. We believe that there are non-cAMP pathways that G15 can act on during GPER-1 activation. Further researches are needed to verify the G15's action on GPER-1 as an antagonist of GPER-1.



**Figure 7.** PCA and G15 effects on GPER-1 related mechanism. **(A)** HUVECs in 96 well were treated with adequate substances (PCA, G1, G15, G15+PCA, G15+G1) for 1 hr after 2 hrs of serum depletion. Graphs are representative of 3 independent experiments. \* indicates  $P < 0.05$  compared to the control and G15 treated group. **(B)** HUVECs were pretreated with adequate substances for 24hrs (PCA, 100  $\mu\text{M}$ ; G1, 3.0  $\mu\text{M}$ ). Then G15 (3.0  $\mu\text{M}$ ) were added for 6 hrs for p-AMPK and AMPK. Blots are representative of 3 independent experiments. \* indicates  $P < 0.05$  compared to the control group. # indicates  $P < 0.05$  compared to the G15 group.

## IV. Discussion

PCA has exhibited various therapeutic effects in different cell types such as vascular smooth muscle cells, cancer cells, and a cardiac animal model.<sup>15,24,25</sup> However, PCA has not been evaluated for its effect against endothelial dysfunction and has rarely been studied in HUVECs. Unlike PCA, GPER-1 has been consistently reported for its role in attenuating atherosclerosis because it regulates the activity of many vasoconstrictors and proliferation of vascular smooth muscle cells.<sup>10</sup> Thus, it is becoming increasingly difficult to ignore the importance of endothelial cells and GPER-1 in developing therapeutic agents against endothelial dysfunction and atherosclerosis.

The activation of GPER-1 by PCA protects endothelial cells in various ways from inflammation *in vitro*. One of them is the inhibition of ROS production, which is closely related to NF- $\kappa$ B. The reduction of ROS by PCA and GPER-1 agonist has shed light on the relationship between GPER-1 and NF- $\kappa$ B. Previous studies have pointed out the beneficial effects of GPER-1 on atherosclerosis, but they have failed to find connections with NF- $\kappa$ B.<sup>26</sup> However, we found that G1 and PCA could down-regulate the secondary molecules involved in NF- $\kappa$ B signaling. Such cytokine-mediated upregulation of NF- $\kappa$ B was shown to implicate HIF-1 $\alpha$ ,<sup>27</sup> CD40 and other adhesion molecules (E-selectin, VCAM-1 and ICAM-1),<sup>28,29</sup> which were effectively inhibited by PCA and GPER-1 agonist. We also showed that PCA and G1 down-regulated the phosphorylation of p38-mitogen activated protein kinase, which also has been recently reported from a previous study using ApoE<sup>-/-</sup> mice.<sup>30</sup> Although other possible mechanisms have yet to be



ruled out, our results strongly suggest a model in which PCA increases GPER-1 to down-regulate inflammatory molecules.

The activation of GPER-1 as a type of GPCR can result in beneficial effects against inflammation. Cyclic-AMP and  $\text{Ca}^{2+}$  are most frequently associated with GPER-1 signaling. GPER-1 couples to  $\text{G}\alpha_s$  resulting in cAMP production and  $\text{G}\alpha_{i/o}$  to partly yield cAMP.<sup>10</sup> PCA and G1 have been shown to increase the production of cAMP, but it remains if the GPCR  $\alpha$  subunit of PCA can or cannot be activated. The activation of GPCR automatically activates regulatory molecules, including GRKs<sup>31</sup> and  $\beta$ -arrestin<sup>32</sup>. These molecules determine the role of GPER-1 once they are desensitized. It still remains unclear whether PCA or G1 can alter the expression of these molecules to change the fate of GPER-1.

PCA and G1 had inhibitory effects against angiogenesis in the Sprout Ring assay. In contrast, G15 treatment showed that it accelerated angiogenesis to a much greater extent than the serum only group. From the MTS assay (Supplementary data), PDGF increased VSMC proliferation, which was decreased by PCA and G1. Treatment with G15 increased proliferation, but this angiogenic effect of G15 was inhibited by treatment with PCA or G1. These results expand the effects of PCA as an anti-angiogenic agent and show that PCA could interact with proteins other than GPER-1 since most GPCRs and their kinases are known to accelerate angiogenesis.<sup>33</sup>

G15, an antagonist of GPER-1, has been recently discovered and its effects have not been evaluated in endothelial cells. Its involvement in blocking estradiol 17 $\beta$ -D-glucuronide-induced cAMP production<sup>34</sup> and upregulation of the angiotensin AT<sub>1</sub> receptor have been reported.<sup>35</sup> Our *in*

*vitro* results, showed that G15 acts as a pro-inflammatory agent to increase the expression of inflammatory markers such as VCAM-1, ICAM-1 and CD40. Also, the pro-inflammatory characteristics of G15 were observed for angiogenesis, neointimal formation and attenuation of re-endothelization. To verify whether PCA can act against the effects of G15, HUVECs were pre-treated with PCA before treatment with G15. The results showed that PCA effectively inhibited the pro-inflammatory effects of G15. Consistent with these results, the CCA of balloon-injured rats showed that PCA inhibited the pro-inflammatory effects of G15 by reducing neointimal hyperplasia. In accordance with the balloon injury results, the endothelia of rat aortas co-treated with PCA and G15 showed noticeable recovery from balloon injury.

To reveal the correlation between HUVECs and aortas, we performed immunohistochemistry for GPER-1, CD40, CD31 and VCAM-1. We have observed that rats co-treated with PCA and G1 had definite expression of CD31 and GPER-1, suggesting that GPER-1 affects endothelial cell survival. Also, the immunohistochemistry results for CD40 and VCAM-1 showed that PCA and G1 effectively inhibited both these molecules, similar to observations from the HUVEC experiment. In contrast, aortas from G15-treated rats did not show expression of either GPER-1 or CD31. Surprisingly, immunohistochemistry for VCAM-1 and CD40 was clearly observed in the vehicle and G15-treated groups. Furthermore, treatment with G15 and PCA or G1 in rats showed recovery of CD31 and GPER-1, indicating that PCA and G1 act through GPER-1 in a similar manner.

To further explain the various roles of PCA in the endothelium, studies on the structure of PCA are required. O'Brien et al<sup>36</sup> showed that aldehyde has therapeutic effects against some human diseases. Therefore, we have compared two different protocatechuic substances, aldehyde and its acid form (data not shown), in order to reveal the structural function of this particular molecule. We showed that protocatechuic acid does not have the same therapeutic effects as the aldehyde form. This provided us with information on the structural importance of this molecule with respect to endothelial dysfunction. Further research will be required to elucidate the structural function of PCA for the development of new drugs against atherosclerosis.

GPER-1 and ring-structured aldehyde may be closely associated with each other. A recent study by Hamza et al<sup>37</sup> showed that hydroxyproline, which is one of the ring-structured aldehydes, activates GPER-1 through a different mechanism from estrogen. They also suggested that it stabilizes the active site of GPER-1 by forming a network of hydrogen bonds between the residues of GPER-1. PCA and 3,4-dihydroxybenzaldehyde share many structural features with hydroxyproline that need to be evaluated to confirm whether PCA acts in a similar manner as hydroxyproline. However, in the present study, we compared data on PCA and G1 and showed that PCA exhibited similar therapeutic effects as G1, thus demonstrating the likelihood that PCA can act like hydroxyproline.

Currently, it is difficult task to find the exact mode of activation by PCA. So, by comparing the effects of G1 and PCA in the presence of G15, it would clarify the function of PCA whether it can act like G1 or GPER-1 agonist in activating cAMP. The results from Supplementary Figure 2A

show that the treatment of PCA or G1 in the presence of G15 decreased cAMP in similar degree in comparison to the HUVECs treated with PCA or G1 without G15. This shows that PCA and G1 share the similar mechanism in interacting with GPER-1 for cAMP activation and that their activity cannot be fully inhibited by the treatment G15. This implicates that PCA can interact with GPER-1 like G1 agonist. Further researches are needed to find whether PCA and GPER-1 bind directly or not. To further verify the relationship between PCA and GPER-1 and G15's intervention in this relationship, we have treated G15 to HUVECs to see whether G15 can inhibit the cAMP activity of GPER-1. In Supplementary Figure 2A shows that G15 has a mild inhibitory effect on cAMP activity. Also, the treatment of G15 with PCA or G1 has decreased activity level compared to PCA or G1 only treated group. This shows that G15, which is unknown for its capability on GPER-1 mechanism, does a slight inhibition on cAMP activity of GPER-1 in HUVECs. Also similar patterns were observed in Supplementary Figure 2B as it mildly inhibits p-AMPK, which is well-known downstream protein of cAMP, increased by PCA and G1. This data suggests G15's inhibitory effect depend less on cAMP inhibition to cause inflammatory and oxidative effects. We believe that there are non-cAMP pathways that G15 can act on during GPER-1 activation. Further researches are needed to verify the G15's action on GPER-1 as an antagonist of GPER-1.

## V. Conclusion

In summary, the present study provides the first evidence that PCA attenuates endothelial dysfunction and atherosclerosis *in vitro* and *in vivo* through activation of GPER-1. These findings indicate that PCA is an important candidate compound for the treatment of atherosclerosis.

## References

1. Endemann DH, Schiffrin EL. Endothelial dysfunction. *J Am Soc Nephrol* 2004;15:1983-92.
2. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. *J Hypertens* 2005;23:7-17.
3. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: Part I. *Circulation* 2003;108:1917-23.
4. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. *Circ Res* 2001;88:1291-8.
5. Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. *Proc Natl Acad Sci U S A* 1996;93:9114-9.
6. Kalin MF, Zumoff B. Sex hormones and coronary disease: a review of the clinical studies. *Steroids* 1990;55:330-52.

7. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. *N Engl J Med* 1996;335:453-61.
8. Clarkson TB, Appt SE. Controversies about HRT--lessons from monkey models. *Maturitas* 2005;51:64-74.
9. Lenfant F, Tremollieres F, Gourdy P, Arnal JF. Timing of the vascular actions of estrogens in experimental and human studies: why protective early, and not when delayed? *Maturitas* 2011;68:165-73.
10. Nilsson BO, Olde B, Leeb-Lundberg LM. G protein-coupled oestrogen receptor 1 (GPER1)/GPR30: a new player in cardiovascular and metabolic oestrogenic signalling. *Br J Pharmacol* 2011;163:1131-9.
11. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. *Science* 2005;307:1625-30.
12. Mercier I, Mader S, Calderone A. Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptor-independent mechanism. *Cardiovasc Res* 2003;59:883-92.
13. Haas E, Bhattacharya I, Brailoiu E, Damjanovic M, Brailoiu GC, Gao X, et al. Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. *Circ Res* 2009;104:288-91.

14. Wei M, Chu X, Jiang L, Yang X, Cai Q, Zheng C, et al. Protocatechuic acid attenuates lipopolysaccharide-induced acute lung injury. *Inflammation* 2012;35:1169-78.
15. Moon CY, Ku CR, Cho YH, Lee EJ. Protocatechuic aldehyde inhibits migration and proliferation of vascular smooth muscle cells and intravascular thrombosis. *Biochem Biophys Res Commun* 2012;423:116-21.
16. Chen J, Zhang J, Xu L, Xu C, Chen S, Yang J, et al. Inhibition of neointimal hyperplasia in the rat carotid artery injury model by a HMGB1 inhibitor. *Atherosclerosis* 2012;224:332-9.
17. Gupta P, Goldenberg DM, Rossi EA, Cardillo TM, Byrd JC, Muthusamy N, et al. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. *Blood* 2012;119:3767-78.
18. Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, D'Amico G, et al. Use of the mouse aortic ring assay to study angiogenesis. *Nat Protoc* 2012;7:89-104.
19. Jeong JY, Lee DH, Kang SS. Effects of chronic restraint stress on body weight, food intake, and hypothalamic gene expressions in mice. *Endocrinol Metab (Seoul)* 2013;28:288-96.
20. Nam YJ, Kim BH, Lee SK, Jeon YK, Kim SS, Jung WJ, et al. Co-occurrence of papillary thyroid carcinoma and mucosa-associated lymphoid tissue lymphoma in a patient with long-



- standing hashimoto thyroiditis. *Endocrinol Metab* (Seoul) 2013;28:341-5.
21. Rodriguez-Calvo R, Guadall A, Calvayrac O, Navarro MA, Alonso J, Ferran B, et al. Over-expression of neuron-derived orphan receptor-1 (NOR-1) exacerbates neointimal hyperplasia after vascular injury. *Hum Mol Genet* 2013;22:1949-59.
  22. Kawabe-Yako R, Ii M, Masuo O, Asahara T, Itakura T. Cilostazol activates function of bone marrow-derived endothelial progenitor cell for re-endothelialization in a carotid balloon injury model. *PLoS One* 2011;6:e24646.
  23. Cho YH, Ku CR, Hong ZY, Heo JH, Kim EH, Choi DH, et al. Therapeutic effects of water soluble danshen extracts on atherosclerosis. *Evid Based Complement Alternat Med* 2013;2013:623639.
  24. Kuriyama I, Nakajima Y, Nishida H, Konishi T, Takeuchi T, Sugawara F, et al. Inhibitory effects of low molecular weight polyphenolics from *Inonotus obliquus* on human DNA topoisomerase activity and cancer cell proliferation. *Mol Med Rep* 2013;8:535-42.
  25. Wei G, Guan Y, Yin Y, Duan J, Zhou D, Zhu Y, et al. Anti-inflammatory effect of protocatechuic aldehyde on myocardial ischemia/reperfusion injury in vivo and in vitro. *Inflammation* 2013;36:592-602.

26. Chakrabarti S, Davidge ST. G-protein coupled receptor 30 (GPR30): a novel regulator of endothelial inflammation. *PLoS One* 2012;7:e52357.
27. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. *Nature* 2008;453:807-11.
28. Hollenbaugh D, Mischel-Petty N, Edwards CP, Simon JC, Denfeld RW, Kiener PA, et al. Expression of functional CD40 by vascular endothelial cells. *J Exp Med* 1995;182:33-40.
29. Geraldès P, Gagnon S, Hadjadj S, Merhi Y, Sirois MG, Cloutier I, et al. Estradiol blocks the induction of CD40 and CD40L expression on endothelial cells and prevents neutrophil adhesion: an ERalpha-mediated pathway. *Cardiovasc Res* 2006;71:566-73.
30. Potthoff SA, Fahling M, Clasen T, Mende S, Ishak B, Suvorava T, et al. Angiotensin-(1-7) modulates renal vascular resistance through inhibition of p38 mitogen-activated protein kinase in apolipoprotein E-deficient mice. *Hypertension* 2014;63:265-72.
31. Kohout TA, Lefkowitz RJ. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. *Mol Pharmacol* 2003;63:9-18.
32. Benovic JL, Kuhn H, Weyand I, Codina J, Caron MG, Lefkowitz RJ. Functional desensitization of the isolated beta-adrenergic receptor by the beta-adrenergic receptor kinase: potential role

- of an analog of the retinal protein arrestin (48-kDa protein). *Proc Natl Acad Sci U S A* 1987;84:8879-82.
33. Milia AF, Salis MB, Stacca T, Pinna A, Madeddu P, Trevisani M, et al. Protease-activated receptor-2 stimulates angiogenesis and accelerates hemodynamic recovery in a mouse model of hindlimb ischemia. *Circ Res* 2002;91:346-52.
  34. Zucchetti AE, Barosso IR, Boaglio AC, Basiglio CL, Mischczuk G, Larocca MC, et al. G-protein-coupled receptor 30/adenylyl cyclase/protein kinase A pathway is involved in estradiol 17 $\beta$ -glucuronide-induced cholestasis. *Hepatology* 2014;59:1016-29.
  35. Koganti S, Snyder R, Gumaste U, Karamyan VT, Thekkumkara T. 2-methoxyestradiol binding of GPR30 down-regulates angiotensin AT(1) receptor. *Eur J Pharmacol* 2014;723:131-40.
  36. O'Brien PJ, Siraki AG, Shangari N. Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. *Crit Rev Toxicol* 2005;35:609-62.
  37. Hamza A, Sarma MH, Sarma RH. Plausible interaction of an alpha-fetoprotein cyclopeptide with the G-protein-coupled receptor model GPR30: docking study by molecular dynamics simulated annealing. *J Biomol Struct Dyn* 2003;20:751-8.

Abstract (in Korean)

**Protocatechuic Aldehyde 의 동맥경화증 억제 기전 및  
G protein-coupled Estrogen Receptor-1 과의 연관성**

<지도교수 이은직>

연세대학교 대학원 의과학과

공병수

Protocatechuic aldehyde (PCA)는 페놀성 알데히드(phenolic aldehyde)로써 동맥경화증에 대한 치료효과가 있다. 비록 PCA가 혈관 평활근 세포(vascular smooth muscle cells)의 증식, 이동 및 혈관 내 혈전생성(intravascular thrombosis)을 억제한다고 알려져 있지만, 아직 근본적인 기전은 규명 되지 않았다. 이 논문에서는, 내피세포와 in vivo 동맥경화 모델에서의 PCA의 혈관 보호 효과와 그것에서의 G protein-coupled estrogen receptor-1 (GPER-1)과의 관계를 확인해보려 한다.

사람 혈관 내피세포 (Human Umbilical Vein Endothelial cells, HUVECs)와 쥐 대동맥 외식편 (Rat aortic explant)에서 PCA 처리 시 cAMP 생성과 GPER-1 발현이 유의미성 있게 증가되는 것을 확인할 수 있었다. PCA와 GPER-1 작용제 (agonist)인 G1은 과산화수소( $H_2O_2$ )에 의해 증가된 활성산소(Reactive oxygen

species, ROS) 생성을 감소시키지만 G15 길항제(antagonist)의 경우에는 반대로 증가시켰다. 또한, G15 에 의한 ROS 증가는 PCA 와 G1 을 함께 처리하였을 때 억제되었다. 비슷한 맥락에서  $TNF\alpha$  에 의해 증가된 염증 표지자들 (VCAM-1, ICAM-1, CD40, phospho-NF- $\kappa$ B, phospho-p38 and HIF-1 $\alpha$ ) 도 PCA 와 G1 에 의해서 의미있게 감소하였다. G15 는  $TNF\alpha$  처럼 염증 표지자들을 증가시키지만 PCA 에 의해서 이것 또한 억제되었다.

내피세포재현성(Re-endothelization), 대동맥 고리 성장(aortic ring sprouting)과 위 내막 형성(neointima formation) assay 에서 Sprague Dawley(SD) 쥐 대동맥을 PCA 혹은 G1 으로 처리하였을 때, 증가된 내피세포재현성, 감소된 대동맥 고리성장과 감소된 위 내막 형성을 확인하였다. 반대로, G15 를 처리한 동물에서는 감소된 내피세포재현성, 증가된 대동맥 고리성장과 위 내막 형성을 확인할 수 있었다. G15 에 의해서 촉진된 효과는 PCA 나 G1 처리에 의해서 억제되었다. 또한 이러한 대동맥의 내피에서 면역조직화학(Immunohistochemistry, IHC) 염색을 진행하였을때, CD31 과 GPER-1 의 증가와 VCAM-1 과 CD40 발현의 억제를 확인할 수 있었다. 반면 G15 의 IHC 결과에서는 반대 양상을 보였다. 이러한 결과를 비추어보았을 때, PCA 는 내피세포에서 동맥경화 억제 효과를 나타내며 이 효과들은 GPER-1 을 통해 조절될 것이라고 생각된다.

---

핵심되는 말: protocatechuic aldehyde, 사람 혈관 내피세포, 내피세포 기능부전, 동맥경화, g protein-coupled estrogen receptor-1